All In Biotech

Drug Trial Radar · NCT06752850

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis.

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

37

Actual

Start

Dec 19, 2024

Primary completion

Nov 17, 2026

Study completion Dec 28, 2026

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of joint bleeds in patients with moderate or severe haemophilia A. The use of imaging assessments will allow for objective detection and monitoring of synovial hypertrophy, and thus expand on the previous findings demonstrating positive effects of once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) on joint health.

Conditions

  • Haemophilia A (Moderate or Severe)
  • Hemophilia, Classic
  • Haemophilia
  • Hemophilia
  • Classic Hemophilia
  • Synovial Hypertrophy

Interventions

  • Efanesoctocog alfaDrug

    50 IU/kg once weekly, Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease.Time frame: Baseline to 12 months

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Sobi Investigational Site

    Milan, Italy

  • Sobi Investigational Site

    Naples, Italy

  • Sobi Investigational Site

    Rozzano, Italy

  • Sobi Investigational Site

    Oslo, Norway

  • Sobi Investigational Site

    Barcelona, Spain

  • Sobi Investigational Site

    Madrid, Spain

  • Sobi Investigational Site

    Seville, Spain

  • Sobi Investigational Site

    Valencia, Spain

  • Sobi Investigational Site

    Gothenburg, Sweden

  • Sobi Investigational Site

    Malmö, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.